CINECA IRIS Institutional Research Information System

SIRAVEGNA, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.978
AS - Asia 4.732
EU - Europa 4.716
OC - Oceania 150
SA - Sud America 128
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 13
Totale 16.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.782
CN - Cina 3.072
IT - Italia 1.412
DE - Germania 648
JP - Giappone 551
GB - Regno Unito 490
FR - Francia 357
ES - Italia 325
SE - Svezia 226
IN - India 214
IE - Irlanda 205
KR - Corea 191
CA - Canada 150
TW - Taiwan 136
HK - Hong Kong 130
NL - Olanda 121
AU - Australia 115
FI - Finlandia 107
BE - Belgio 101
CH - Svizzera 95
SG - Singapore 87
GR - Grecia 84
BR - Brasile 83
TR - Turchia 81
PL - Polonia 74
DK - Danimarca 69
UA - Ucraina 66
RU - Federazione Russa 60
VN - Vietnam 59
RO - Romania 43
AT - Austria 42
MX - Messico 42
NO - Norvegia 38
TH - Thailandia 38
NZ - Nuova Zelanda 35
PT - Portogallo 35
HU - Ungheria 29
CZ - Repubblica Ceca 28
IL - Israele 28
ID - Indonesia 20
MY - Malesia 20
EG - Egitto 17
IR - Iran 17
AR - Argentina 16
SA - Arabia Saudita 15
CO - Colombia 11
AM - Armenia 10
CL - Cile 10
PK - Pakistan 10
ZA - Sudafrica 10
BA - Bosnia-Erzegovina 9
LB - Libano 9
HR - Croazia 8
SI - Slovenia 8
SK - Slovacchia (Repubblica Slovacca) 7
AE - Emirati Arabi Uniti 6
BN - Brunei Darussalam 6
DZ - Algeria 6
EU - Europa 6
NG - Nigeria 6
BG - Bulgaria 5
IS - Islanda 5
JO - Giordania 5
LU - Lussemburgo 5
PH - Filippine 5
RS - Serbia 5
AP - ???statistics.table.value.countryCode.AP??? 4
EC - Ecuador 4
EE - Estonia 4
KE - Kenya 4
OM - Oman 4
GE - Georgia 3
KZ - Kazakistan 3
MO - Macao, regione amministrativa speciale della Cina 3
MT - Malta 3
SN - Senegal 3
A1 - Anonimo 2
ET - Etiopia 2
KW - Kuwait 2
MK - Macedonia 2
PE - Perù 2
QA - Qatar 2
TZ - Tanzania 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CU - Cuba 1
CY - Cipro 1
GH - Ghana 1
HN - Honduras 1
IQ - Iraq 1
LK - Sri Lanka 1
PA - Panama 1
PR - Porto Rico 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 16.769
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.005
Beijing 608
Shanghai 477
Houston 415
Chandler 368
Fairfield 353
Redwood City 297
Guangzhou 240
Torino 240
Wilmington 199
Ashburn 197
Woodbridge 193
Tokyo 186
Dublin 185
Seattle 184
Cambridge 177
Hangzhou 174
Dearborn 137
Nanjing 134
New York 115
Milan 102
Pisa 84
Rome 84
Wuhan 82
Taipei 78
Villeurbanne 77
Nyköping 75
Medford 69
Zhengzhou 64
London 60
Chengdu 56
Duncan 55
Singapore 54
Boston 52
San Diego 52
Jacksonville 50
Princeton 49
Turin 48
Seoul 47
Barcelona 46
Tianjin 46
Los Angeles 43
Rochester 42
Shenyang 42
Madrid 41
Ottawa 41
Buffalo 40
Fremont 40
Paris 40
Warsaw 40
Norwalk 37
Changsha 36
Chongqing 36
Chicago 35
Munich 35
Berlin 34
Jinan 34
Xian 29
Brussels 28
Istanbul 28
Amsterdam 27
Central District 27
Lappeenranta 27
Boardman 26
Helsinki 26
Melbourne 25
Nanchang 25
Philadelphia 25
Phoenix 25
Atlanta 24
Southend 24
Central 23
Shenzhen 23
Vienna 23
Grafing 22
Hefei 22
Kunming 22
Mainz 22
San Francisco 22
Washington 22
Baltimore 21
Heidelberg 21
Pune 21
Bangkok 20
Bologna 20
Harbin 20
Oslo 20
Redmond 20
Toronto 20
Utrecht 20
Aioicho 19
Dallas 19
Dong Ket 19
Nutley 19
Fuzhou 18
Ludwigshafen 18
Moscow 18
Athens 17
Columbus 17
Hong Kong 17
Totale 8.781
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.864
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.675
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.112
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.045
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies 773
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 688
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 549
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 539
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 447
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 416
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 358
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition 355
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 286
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 277
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 264
How liquid biopsies can change clinical practice in oncology 230
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients 218
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor 214
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 205
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 189
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. 177
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 175
Minimal residual disease in breast cancer: in blood veritas. 163
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 156
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 147
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 144
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma 141
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 139
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 138
Integrating liquid biopsies into the management of cancer 109
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 107
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer 107
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma 104
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers 89
Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-Amplified esophagogastric cancer 85
Liquid biopsies to evaluate early therapeutic response in colorectal cancer 83
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours 75
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer 73
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 62
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know 48
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 41
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer 37
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. 31
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 26
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers 18
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 2
Totale 17.181
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.788
article - articoli 0
book - libri 0
conference - conferenze 265
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.053
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019548 0 0 0 0 0 0 0 0 0 0 318 230
2019/20202.638 225 176 200 272 196 330 194 194 253 265 211 122
2020/20212.810 140 146 174 210 251 221 256 186 293 303 220 410
2021/20222.993 382 377 322 442 168 148 184 188 189 140 251 202
2022/20232.064 167 192 119 202 158 271 155 154 207 124 173 142
2023/20241.944 187 213 182 179 193 189 180 205 76 218 122 0
Totale 17.181